Greenwich LifeSciences Extends Lock-up of Directors and Offi

Greenwich LifeSciences, Inc. , a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have... | December 1, 2022

Related Keywords

, Greenwich Lifesciences Inc , Md Anderson Cancer Center , Company Twitter , Baylor College Of Medicine , Nasdaq , Greenwich Lifesciences , Patients Seeking , Baylor College , Breast Cancer , Cancer Center , Dimer Binding Assay , Nc Stock Exchange , News , Information , Press Release , Greenwich , Iopharmaceutical , Company , Ocused , N , The , Development , F , Immunotherapy , O , Prevent , Breast , Dancer , Recurrences , Patients , Ho Glsi Us3968791083 ,